CS Pharma Holdings

CS Pharmaceuticals (CSP) is a multinational biopharmaceutical company headquartered in London, dedicated to licensing and commercializing innovative therapies for the Greater China market. The company focuses on therapeutic areas with significant unmet medical needs, including rare diseases, ophthalmology, and oncology. CSP leverages its deep expertise in Chinese regulatory pathways and commercial infrastructure to provide a bridge for Western biotech companies looking to expand into the region. Their lead program, vamorolone, is a first-in-class dissociative steroid for Duchenne muscular dystrophy licensed from Santhera Pharmaceuticals. Through strategic global partnerships, CSP aims to accelerate the availability of life-changing medicines to patients across China.